Literature DB >> 1329251

Effects of two dosages of subcutaneous low molecular weight heparin (Parnaparin) and of unfractionated heparin on fibrin formation and lipolysis in acute myocardial infarction.

G Melandri1, A Branzi, F Semprini, V Cervi, B Magnani.   

Abstract

Although low molecular weight heparins (LMWH) have been extensively investigated for the prophylaxis and treatment of venous thromboembolism in surgical environments, few data in acute myocardial infarction are available in the literature. In this study two dosages of a new LMWH, Parnaparin, and unfractionated heparin (UF) were investigated in 50 pts with acute myocardial infarction. 20 pts received UF (15.000 units, three subcutaneous injections, Group 1), 20 pts received Parnaparin (6.400 units, single injection, Group 2) and 10 pts received a higher dose of Parnaparin (12.800 units, single injection, Group 3). Similar fibrinopeptide A (FpA) levels were observed in Group 1 and Group 2. In Group 3 the dosage of Parnaparin resulted in a significant prolongation of the APTT and in lower FpA levels. Fibrin formation was decreased by Parnaparin in a concentration-dependent way, according to both the anti-Xa activity and the APTT ratio. Parnaparin did not result in a significant increase in free fatty acid concentration, in comparison with UF. Thus, Parnaparin may offer the advantage of a single subcutaneous injection in patients with acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329251     DOI: 10.1016/0049-3848(92)90184-c

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

1.  Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.

Authors:  Xu-Kai Wang; Ye Zhang; Cheng-Ming Yang; Yan Wang; Guang-Yao Liu
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 2.  Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders.

Authors:  J E Frampton; D Faulds
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

Review 3.  Parnaparin : a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders.

Authors:  Kate McKeage; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  Update on the clinical use of the low-molecular-weight heparin, parnaparin.

Authors:  Giuseppe Camporese; Enrico Bernardi; Franco Noventa
Journal:  Vasc Health Risk Manag       Date:  2009-10-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.